STOCK TITAN

Alvotech - ALVO STOCK NEWS

Welcome to our dedicated news page for Alvotech (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alvotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alvotech's position in the market.

Rhea-AI Summary
Alvotech, a biotech company, accepted an offer from investors to sell 10,127,132 ordinary shares for USD 166 million. The transaction is at a purchase price of USD 16.41 per share, aiming to use the proceeds for corporate purposes, production capacity, and biosimilar launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
The FDA has approved SIMLANDI (adalimumab-ryvk) as an interchangeable biosimilar to Humira for various arthritis conditions and other diseases in the U.S., marking a significant milestone in Alvotech and Teva's strategic partnership. SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira with interchangeable exclusivity for the 40mg/0.4ml injection. The approval is based on a comprehensive clinical development program, positioning SIMLANDI to offer cost savings and additional treatment options for patients in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alvotech (ALVO) settles with Johnson & Johnson for AVT04 biosimilar to Stelara in Japan, Canada, and EEA. Market approvals granted, pending in the U.S. Launch dates set for various global markets. Commercial partners named for different regions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announced positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to Prolia® and Xgeva®. The study assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, meeting its primary endpoints. Prolia® and Xgeva® are indicated for the treatment of bone disease, with combined net revenues worldwide from sales of Prolia and Xgeva over US$6 billion in the last twelve months before September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
none
-
Rhea-AI Summary
Alvotech (ALVO) announces the conclusion of the FDA reinspection of its facility in Iceland, receiving a form 483 with one observation. The company expects to provide a response to the FDA soon and aims to receive approval for AVT02 and AVT04 by February 24, 2024, and April 16, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
-
Rhea-AI Summary
Alvotech (ALVO) has announced the conclusion of the FDA reinspection of its facility in Iceland, receiving a form 483 with one observation. The company expects to provide a response to the FDA shortly and anticipates approval for AVT02 and AVT04 in the U.S. by February 24, 2024, and April 16, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
Rhea-AI Summary
STADA and Alvotech receive marketing authorization for Uzpruvo, a biosimilar to Stelara, in the European Economic Area, paving the way for biosimilar competition in the €2.5 billion EU ustekinumab market after the expiry of intellectual-property rights in July 2024. The European Commission's decision offers the potential to expand patient access through competition, with Uzpruvo being based on comprehensive package comprising analytical, non-clinical, and clinical similarity data, including a confirmatory comparative efficacy and safety clinical trial in patients with moderate to severe chronic plaque-type psoriasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announced positive top-line results from a confirmatory clinical study for AVT06, their proposed biosimilar to Eylea® (aflibercept), meeting its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD). This development showcases the advantage of their integrated development and manufacturing platform, allowing the company to pursue a diversified global biosimilar strategy. Eylea is a widely used biologic for the treatment of eye disorders, with cumulative global sales in the last twelve months before September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
clinical trial
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announced positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® (golimumab), meeting its primary endpoints. The study assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects. Alvotech's current portfolio includes one launched product, one approved biosimilar, and four biosimilar candidates in clinical studies, including AVT05.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
clinical trial
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) will release financial results for the first nine months of 2023 after the U.S. markets close on Tuesday, November 28, 2023. A business update conference call for analysts will be held on Wednesday, November 29, 2023, at 8:00 am ET (1 pm GMT). Live audio of the conference call will be webcast and available to the public. Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
Alvotech

Nasdaq:ALVO

ALVO Rankings

ALVO Stock Data

4.59B
63.00M
72.8%
6.98%
0.04%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Iceland
Reykjavik

About ALVO

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a